Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Shares Issued Shares Repurchased

Growth Metrics

Ratios

Avai Bio (AVAI) Depreciation and Depletion (2019 - 2024)

Avai Bio's Depreciation and Depletion history spans 2 years, with the latest figure at $18812.0 for Q4 2020.

On a quarterly basis, Depreciation and Depletion rose 129.69% to $18812.0 in Q4 2020 year-over-year; TTM through Dec 2020 was -$35079.0, a 240.35% decrease, with the full-year FY2024 number at $1500.0, changed N/A from a year prior.
Depreciation and Depletion hit $18812.0 in Q4 2020 for Avai Bio, up from -$1432.0 in the prior quarter.
Over the last five years, Depreciation and Depletion for AVAI hit a ceiling of $22821.0 in Q2 2020 and a floor of -$75280.0 in Q1 2020.